We have read with great interest the results of the meta-analysis conducted by Li
and colleagues [
[1]
], demonstrating that Janus kinase (JAK) inhibitors are a safe treatment option for
patients with active ankylosing spondylitis (AS). Authors showed that JAK inhibitors
might be an efficacious and safe drug class for patients with AS not responding to
currently recommended biologic therapies.- Li S.
- Li F.
- Mao N.
- Wang J.
- Xie X.
Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis:
a systematic review and meta-analysis.
Eur J Intern Med. 2022; ([published online ahead of print, 2022 Apr 20]) (S0953-6205(22)00143-1)https://doi.org/10.1016/j.ejim.2022.04.007
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.Eur J Intern Med. 2022; ([published online ahead of print, 2022 Apr 20]) (S0953-6205(22)00143-1)https://doi.org/10.1016/j.ejim.2022.04.007
- Cardiovascular events in ankylosing spondylitis: an updated meta-analysis.Semin Arthritis Rheum. 2015; 44: 551-555https://doi.org/10.1016/j.semarthrit.2014.10.007
- The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis.Angiology. 2019 Jul; 70: 492-500https://doi.org/10.1177/0003319718814309
- Increased levels of oxidative stress markers, soluble cd40 ligand, and carotid intima-media thickness reflect acceleration of atherosclerosis in male patients with ankylosing spondylitis in active phase and without the classical cardiovascular risk factors.Oxid Med Cell Longev. 2017; (2017)9712536https://doi.org/10.1155/2017/9712536
- Risk of cardiovascular and venous thromboembolic events associated with janus kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis.J Clin Rheumatol. 2022; 28: 69-76https://doi.org/10.1097/RHU.0000000000001804
- Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.Gastroenterology. 2020; 158 (e12): 1554-1573https://doi.org/10.1053/j.gastro.2020.01.001
- ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.N Engl J Med. 2022 Jan 27; 386: 316-326https://doi.org/10.1056/NEJMoa2109927
Article info
Publication history
Published online: June 03, 2022
Accepted:
May 30,
2022
Received:
May 10,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
